Health News Releases

  • Today August 25
블라블라
August 24, 16:00
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54590997&newsitemid=20260818063761&lan=en-US&anc
August 24, 11:00
Novotech Strengthens Presence in Japan with Opening of Tokyo Office
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment bui
August 19, 17:40
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md
August 12, 14:01
Align Technology Prevails in China Patent Infringement Action Against Angelalign
Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan
August 11, 10:50
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
BeOne Medicines Ltd (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54586664&newsitemid=20260810801799&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=
August 10, 10:50
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings
An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Co
Eight Ophthalmologists at BGN Eye Clinic Jamsil Specializing in SMILE LASIK, LASEK, ICL, Presbyopia
August 10, 08:00
Is a Lower SMILE LASIK Price Really the Best Choice? Three Things to Consider Beyond Cost
Dr. Se-Kwang Park, Chief Ophthalmologist at BGN Eye Clinic Jamsil, has advised patients on what to consider when selecting a clinic for SMILE LASIK surgery. For many people considering vision corre
August 07, 11:20
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54583421&newsitemid=20260805570642&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md
August 06, 10:43
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/stock-information/)) announced that the U.S. Food and Drug Administration (FDA) approved (https://www.fda.gov/news-events/press-announcement
August 05, 14:30
WHOOP Expands Commitment to Women’s Health by Including One-Year Subscription of Natural Cycles° App in Membership
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%2F%3Fsrsltid%3DAfmBOoqrUNUmqB7UR9PSkcUqTlIlQZFv-cFnFEHe-4KarW-TDybGdsAu&esheet=54582456&newsitemid=20260804399367
August 05, 11:50
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available
August 04, 09:50
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC
SS&C Technologies Holdings, Inc. (https://www.ssctech.com/?utm_campaign=SSC2026-Enterprise-Press-Release-0826&utm_medium=pressrelease&utm_source=prnews&utm_content=First-Plus-SSNC) (Nasdaq: SSNC) toda
July 31, 13:40
White Paper Examines Early Clinical Development of B-Cell Depletion Therapies in Autoimmune Disease
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, B-Cell Depletion in Autoimmune Disease: Considerations for
July 30, 15:52
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54578194&newsitemid=20260727883646&lan=en-US&anc
July 30, 15:40
VDyne Announces First Patient Treated in TRIVITA US IDE Pivotal Study of the TriNova™ Transcatheter Tricuspid Valve Replacement System
VDyne Inc. (“VDyne”), a privately held medical device company developing an innovative transcatheter tricuspid valve replacement (TTVR) system, today announced that the first patient has been enrolled
July 30, 15:30
Copeland Enters into Exclusive Negotiations to Acquire Dickson, Advancing Cold Chain Leadership
Copeland, a global leader in compression technologies and controls solutions, today announced its entry into exclusive negotiations towards the purchase of Dickson, a portfolio company of May River Ca
July 30, 11:50
Xpress Genomics Joins Parse Biosciences’ Certified Service Provider Network
Parse Biosciences (https://www.parsebiosciences.com/), the leading provider of scalable and accessible single cell sequencing, and a QIAGEN company, today announced that Xpress Genomics (https://xpres
July 24, 16:41
Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results
Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the second quarter and first half
July 24, 11:15
Kirin and Blackmores Team Up to Release Cognitive Function Support Supplements in Australia and New Zealand Formulated with Kirin Group’s Cognizin® Citicoline
Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and Blackmores Limited (Blackmores), Kirin’s group company and Australia’s leading natural health company, are proud to announce the launch
July 23, 15:31
Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year
Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. · Net sales reached 3.134 billion USD, surpassing 3 billi
July 22, 11:30
Zayed Sustainability Prize’s Beyond2020 Initiative Strengthens Healthcare Resilience for Over 200,000 People in India
Beyond2020, the flagship initiative launched by the Zayed Sustainability Prize, the UAE’s pioneering award for innovative solutions to global challenges, today announced the deployment of solar-powere
July 21, 14:20
Brenus Pharma Welcomes New European and Asia-Pacific Life Sciences Investors in Series A Extension
Brenus Pharma today announced an €11 million ($12.6M) extension to its Series A round, bringing total capital raised since inception to €38 million ($43.5M). This funding reflects strong execution acr
July 21, 13:30
HistoSonics Opens Expanded Histotripsy Training Center in Hong Kong
HistoSonics today announced the opening of its expanded Histotripsy Training Center in Hong Kong, reinforcing the city’s position as a leading hub for physician education, clinical collaboration, and
July 21, 09:25
Clinigen Appoints Greg Skalicky as Chief Executive Officer
Clinigen, the global pharmaceutical services company dedicated to accelerating access to critical medicines worldwide, today announced the appointment of Greg Skalicky as Group Chief Executive Officer
July 20, 15:30
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin - its premium regenerative skincare brand - across the JPAC region. The brand recently launched i
July 19, 13:51
Aqemia and Sanofi Expand Their Research Collaboration
Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the
July 19, 13:30
Crown Bioscience Joins C-Path's NAMs Developer Coalition to Advance Human-Relevant Models in Drug Development
Crown Bioscience (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.crownbio.com%2F&esheet=54570432&newsitemid=20260716657544&lan=en-US&anchor=Crown+Bioscience&index=1&md5=de38f797
July 19, 13:05
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54571620&newsitemid=20260716820927&lan=en-US&anchor=TSE%3A4
July 19, 11:50
Garvan Institute of Medical Research Joins Parse Biosciences’ Certified Service Provider Network
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fparsebiosciences.com&esheet=54570389&newsitemid=20260715791600&lan=en-US&anchor=Parse+Biosciences&index=1&md5=9f32bd
July 19, 11:30
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
Agenus (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.agenusbio.com&esheet=54564391&newsitemid=20260706344475&lan=en-US&anchor=Agenus&index=1&md5=19d18ed2bf133f951b7929138bb9ddf
HistoSonics Edison® Histotripsy System
July 16, 13:30
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform
HistoSonics (https://histosonics.com/), today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histot
July 16, 12:00
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
Agenus (https://www.agenusbio.com/) Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of app
July 15, 16:10
Neuraptive Therapeutics Licenses Innovative Bioresorbable Nerve Stimulation Technology from Washington University in St. Louis
Neuraptive Therapeutics, Inc., a clinical-stage biotech company focused on peripheral nerve injuries, announced today that it has secured an exclusive license from Washington University in St. Louis f
July 15, 16:00
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nomin
July 15, 09:40
European Commission Approves Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation
Merck, a leading global science and technology company, today announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indica
Actus Nutrition achieves Certified B Corporation status.
July 14, 13:40
Actus Nutrition Achieves Certified B Corporation™ Status
Actus Nutrition today announced that it has achieved Certified B Corporation™ status, joining a global community of businesses that value social and environmental performance, accountability, and tran
July 14, 10:20
Universal Orthodontic Lab Appoints Dr. Ryo Hamanaka, DDS, PhD as Chief Clinical Officer and Head of Experimental Applications Group
Universal Orthodontic Lab (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Funiortholab.com&esheet=54567927&newsitemid=20260709262005&lan=en-US&anchor=Universal+Orthodontic+Lab&index=1
July 13, 09:28
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
Takeda (TSE:4502/NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) today anno
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders
July 10, 10:40
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders
Published today in Schizophrenia Bulletin (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdoi.org%2F10.1093%2Fschbul%2Fsbag082&esheet=54556765&newsitemid=20260618626815&lan=en-US&an
WHOOP Names Dirk-Jan “DJ” van Hameren (left) Chief Marketing Officer as Member Base Surpasses 3 Mill
July 09, 13:55
WHOOP Names Dirk-Jan “DJ” van Hameren Chief Marketing Officer as Member Base Surpasses 3 Million
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%2F%3Fsrsltid%3DAfmBOooOTY-AZkUZ-01Qee0dSrZN_xMoMokSbRiKqYhxdZZVXjMKa_-U&esheet=54566384&newsitemid=20260708877245
July 09, 09:00
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy desi
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Develop
July 08, 15:30
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocyt
July 08, 11:00
Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status
July 08, 09:30
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore
Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) s
July 07, 14:38
Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns
Galderma (SWX:GALD) has unveiled results from the world’s most extensive skin quality profiling survey, finding that skin quality concerns are widespread, can impact emotional wellbeing and, while dif
July 07, 11:20
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (I
July 03, 10:30
Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member
Brenus Pharma, today announced key appointments to its board of directors. The company welcomes Eric DESSERTENNE, as President & Chairman of the board, succeeding co-founder Jacques GARDETTE, who will
July 02, 11:30
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-311
July 01, 14:15
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administra
July 01, 11:40
Medisca Enters Its Next Chapter Under Founder Antonio Dos Santos
For more than 35 years, Dos Santos has helped shape Medisca into a global leader in pharmaceutical compounding. As Chief Executive Officer, he will lead the company’s long-term strategy, with a focus
25 per page50 per page75 per page100 per page